Antiretroviral Therapy
VIDEO: IAS-USA endorses off-label use of long-acting ART for HIV
DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.
Long-acting ART for HIV effective for people who struggle with daily pills
Results from an ongoing trial showed that long-acting injectable ART for HIV is effective for people who struggle to consistently take a daily course of medication, the NIH and ViiV Healthcare announced.
Mortality among people with HIV on ART significantly declined from 1996 to 2020
Rates of cause-specific mortality among people with HIV on ART declined between 1996 and 2020, with the largest reductions being in rates of AIDS-related mortality, researchers found.
Pitavastatin lowers plaque volume, progression in lower-risk patients with HIV
PHILADELPHIA — Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk for CVD, according to new data from the REPRIEVE trial.
Obesity leads to suboptimal antiretroviral drug responses in people with HIV
Using physiologically based pharmacokinetic modeling combined with observed clinical data, researchers determined that obesity can lead to reduced exposure and response to antiretroviral drugs.
Long-acting ART, support services could increase HIV viral suppression, survival
Long-acting injectable cabotegravir/rilpivirine paired with extensive support services for nonsuppressed people with HIV with adherence barriers would likely increase viral suppression and improve survival, researchers found.
HIV trial participants remain virally suppressed on dolutegravir monotherapy
Early combination ART initiation during primary HIV infection can lead to sustained virological suppression after switching to dolutegravir monotherapy, data from the EARLY-SIMPLIFIED study suggests.
ART ‘starter packs’ help link patients to HIV care from emergency department
A hospital in California offered patients who tested positive for HIV in the emergency department an initial 14-day supply of ART, believing it would minimize treatment barriers and encourage them to seek outside care.
HIV viral rebound rare after 2 years of consistent suppression, study finds
A study of almost 4,000 people with HIV and sustained 2-year period of viral suppression found that they were unlikely to experience viral rebound over the next 2 years, supporting treatment as prevention as an HIV prevention strategy.
Children lag behind adults in HIV treatment, testing
Children are falling far behind adults when it comes to testing and treatment for HIV, according to a new study published in Pediatrics.